IL-6 regulates CD44 cell surface expression on human myeloma cells

被引:32
作者
Vincent, T
Mechti, N
机构
[1] CNRS, UMR 5160, F-34094 Montpellier 5, France
[2] INSERM, U475, Montpellier, France
[3] Hop St Eloi, Immunol Lab, Montpellier, France
关键词
myeloma; CD44; extracellular matrix; gene expression; hyaluronan;
D O I
10.1038/sj.leu.2403333
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Multiple myeloma ( MM) is a progressive B-lineage neoplasia characterized by the accumulation of slow proliferative malignant plasma cells in the bone marrow compartment where the microenvironment seems to be favorable for their growth and survival. Heparan sulfate proteoglycans such as syndecan-1 and CD44 are thought to play a central role in the survival signals provided by these bone marrow survival niches, which require complex interactions between myeloma cells, extracellular matrix, stromal cells and soluble factors. In this report, we demonstrate that interleukin-6 (IL-6), the main survival and growth factor for myeloma cells, strongly increases CD44 gene expression. In addition, we show that IL-6 modulates CD44 RNA alternative splicing and induces the overexpression of all CD44 variant exons. Finally, we show that IL-6-induced CD44 cell surface molecules have a functional polarized membrane distribution. As IL-6 secretion induced from bone marrow stromal cells by myeloma cells is partly mediated through direct cell-to-cell interaction involving CD44 adhesion molecules, our findings suggest that a CD44/IL-6 amplification loop plays a crucial role in myeloma cell survival.
引用
收藏
页码:967 / 975
页数:9
相关论文
共 71 条
[1]  
Anderson Kenneth C., 2000, Hematology Am Soc Hematol Educ Program, P147
[2]  
ARAI T, 1994, J BIOL CHEM, V269, P20388
[3]   CD44 IS THE PRINCIPAL CELL-SURFACE RECEPTOR FOR HYALURONATE [J].
ARUFFO, A ;
STAMENKOVIC, I ;
MELNICK, M ;
UNDERHILL, CB ;
SEED, B .
CELL, 1990, 61 (07) :1303-1313
[4]  
Asosingh K, 2001, CANCER RES, V61, P2862
[5]  
Asosingh K, 2000, CANCER RES, V60, P3096
[6]  
Barbour AP, 2003, CANCER RES, V63, P887
[7]   CD130 rather than CD126 expression is associated with disease activity in multiple myeloma [J].
Barillé, S ;
Thabard, W ;
Robillard, N ;
Moreau, P ;
Pineau, D ;
Harousseau, JL ;
Bataille, R ;
Amiot, M .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 106 (02) :532-535
[8]  
BARILLE S, 1995, BLOOD, V86, P3151
[9]   BIOLOGIC EFFECTS OF ANTI-INTERLEUKIN-6 MURINE MONOCLONAL-ANTIBODY IN ADVANCED MULTIPLE-MYELOMA [J].
BATAILLE, R ;
BARLOGIE, B ;
LU, ZY ;
ROSSI, JF ;
LAVABREBERTRAND, T ;
BECK, T ;
WIJDENES, J ;
BROCHIER, J ;
KLEIN, B .
BLOOD, 1995, 86 (02) :685-691
[10]   SERUM LEVELS OF INTERLEUKIN-6, A POTENT MYELOMA CELL-GROWTH FACTOR, AS A REFLECT OF DISEASE SEVERITY IN PLASMA-CELL DYSCRASIAS [J].
BATAILLE, R ;
JOURDAN, M ;
ZHANG, XG ;
KLEIN, B .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (06) :2008-2011